Ovarian Cancer
Conditions
Keywords
Ovarian cancer, Platinum resistant
Brief summary
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.
Detailed description
While this study was planned as two-part study consisting of a Phase 1b and a Phase 2 portion, the sponsor decided not to proceed with the Phase 2 portion. The Phase 1b portion of the study was a multicenter, 2-group, open-label design to evaluate the safety and tolerability of AVB-S6-500 combined with PLD or Pac in subjects with platinum-resistant recurrent ovarian cancer. The decision to enroll in the Phase 2 portion of the study was to be driven by the recommendation of a safe and tolerable dose of AVB-S6-500 in combination with each chemotherapy backbone; however, enrollment into the Phase 2 portion was not initiated per Sponsor decision. Given that sufficient data were obtained in the Phase 1b portion AVB-S6-500 + Pac group, the decision was made to pursue a randomized Phase 3 to further study the benefit of this combination versus paclitaxel alone in patients with platinum resistant ovarian cancer.
Interventions
DRUGAVB-S6-500
AVB-S6-500 is experimental drug
DRUGPaclitaxel (Pac)
Paclitaxel is active comparator
DRUGPegylated liposomal doxorubicin (PLD)
PLD is active comparator
OTHERPlacebo
Placebo comparator
Sponsors
Aravive, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer. * Platinum resistant disease, defined as progression within ≤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy * Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy * Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug * Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy * Must have ovarian cancer that is measurable according to RECIST 1.1 * ECOG performance status of 0-1 * Normal gastrointestinal (GI), bone marrow, liver and kidney function * At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500
Exclusion criteria
* Primary platinum-refractory disease (defined as progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen) * Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial * Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study * Significant cardiac disease history * Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix * Symptomatic CNS metastasis or metastases * Serious active infection requiring IV antibiotics and/or hospitalization at study entry * Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C * Has had paracentesis for ascites within 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) | 6 months | Measured by the number of patients with AEs in Phase 1 portion of the study. |
| Anti-tumor activity of AVB-S6-500 in combination with PLD | 18 months | Measured by progression free survival (PFS) in patients receiving AVB-S6-500+PLD versus patients receiving Placebo+PLD in Phase 2 portion of the study. |
| Anti-tumor activity of AVB-S6-500 in combination with Pac | 18 months | Measured by progression free survival (PFS) in patients receiving AVB-S6-500+ Pac versus patients receiving Placebo+Pac in Phase 2 portion of the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics: t1/2 | 18 months | Apparent terminal half-life of AVB-S6-500. |
| Pharmacodynamic marker assessment | 18 months | Change from the baseline in GAS6 serum levels. |
| Anti-drug antibody (ADA) titers | 18 months | Change from baseline in ADA titer. |
| Objective response rate | 18 months | Proportion of subjects who have a partial or complete response to therapy relative to baseline as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria. |
| Pharmacokinetics: AUC | 18 months | Area under the AVB-S6-500 concentration-time curve. |
| Duration of response (DOR) | 18 months | Measured from the date of partial or complete response to therapy until the cancer progresses. |
| Overall survival | 30 months | Time following the treatment until death. |
| CA-125 response rate | 18 months | Proportion of subjects with a minimum 50% reduction in CA-125 serum levels lasting for 28 days relative to baseline CA-125 serum levels. |
| Quality of Life(QOL) | 18 months | Subject QOL will be assessed every 8 weeks during treatment using the Functional Assessment Of Cancer Therapy - Ovarian Cancer (FACT-O) questionnaire, which consists of 4 subscales: physical well-being (7 questions), social/family well-being (7 questions), emotional well-being (6 questions), and functional well-being (7 questions), and 12 additional concerns specific to ovarian cancer. All items are rated on a 5 point scale with 0 not at all and 4 very much. The scoring algorithm allows for eight summary scales: the four core well-being subscales, a subtotal of the 27 core items, a subtotal of the 12 ovarian-specific additional concerns, a grand total of the 39 items, and a trial outcome index (sum of the 17 physical and functional wellbeing items plus the 12 ovarian-specific items). |
| Disease control rate | 18 months | Proportion of subjects who have a complete or partial response to therapy or maintain stable disease. |
| Pharmacokinetics: Cmax | 18 months | Maximum observed AVB-S6-500 concentration. |
| Pharmacokinetics: Tmax | 18 months | Time of maximum observed AVB-S6-500 concentration. |
Countries
United States
Outcome results
None listed